Questions Regarding Data Protection If you have any questions about any of the privacy or data protection issues, please contact us via: Postal address: Vision Healthcare Group, Grote Markt 41, 8500 Kortrijk, Belgium 2026 Vision Healthcare Group BE 0685.849.188 Last updated: 2026-05-27 100% satisfaction guarantee Free delivery above 40 Contact us Premium GLP-1 night-time fat burner Contents: 1x Slimmium Night Burner GLP-1 - Deep Sleep & Weight-Loss Support 2-Pack 270 gs/60 days Gluten-Free GMP Certified Lactose-Free Vegan Vegetarian Made in the EU HACCP Certified Cruelty-Free Paraben-Free Lab Tested Chemical-Free *Disclaimer: The effects of the product may vary between individuals and could differ from those described on the website
If energy dips are making it harder to stay consistent, a Weight Loss Boost supplement may fit into your routine alongside treatment support

FDA warning label updates have progressively acknowledged these additional serious complications: Gallbladder disease (March 2022): Increased risk of cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) requiring surgical removal, with many patients developing symptoms severe enough to necessitate emergency cholecystectomy procedures Intestinal obstruction and ileus (September 2023): FDA acknowledged reports of intestinal blockages that halt normal bowel movement, potentially leading to bowel perforation, sepsis, and death without emergency intervention Pulmonary aspiration during anesthesia (November 2024): Recognition that delayed gastric emptying causes patients to retain food in stomachs far longer than expected, creating aspiration risks when undergoing procedures requiring sedation or general anesthesia Severe gastrointestinal adverse reactions (January 2025): FDA added warnings about serious GI events including severe gastroparesis symptoms and complications requiring hospitalization or surgical intervention The fact that patients who began treatment in 2017, 2018, or 2019 received medications without warnings about ileus, pulmonary aspiration, or severe gastroparesis demonstrates the alleged failure to provide timely and adequate disclosures about serious complications that medical science now clearly links to these medications

Call us at 212-265-2724